Accurant Biotech is a Contract Research Organization (CRO) focusing on immune-based and cell-based method development, method validation, and sample analysis in support of preclinical and clinical trials for biological drug development.
Who We Are
We provide one-stop services of biological analysis for global pharma and biotech companies. Our services include preparation of large molecule bioanalysis assay development and validation of bioanalytical methodology and sample analysis in compliance with GLP regulations.
The founder team is composed of industry experts and researchers with years of experience in big pharma companies, large molecule biologics bioanalysis experts, or long-standing committee members of several relevant associations in China and the US.
Accurant Biotech has operations in 3 different cities in China and the US. The global operation setup enables Accurant Biotech to provide streamlined services for multi-site clinical trials to support biologics drug development.
Accurant Biotech Ningbo site was established in Ningbo High-Tech zone in October 2017 with a registered capital of 10 million RMB. Through the elite talent program, the company was endorsed by the government of Ningbo with an incubator fund and laboratory facilities in 2017. In 2018, Accurant was awarded the top 10 “Most Investable Startups” in Ningbo.
What We Do
CAR-T PK/PD, PK for Gene Therapy (ECL, sandwich method)
ECL, biotin Ru labeled Bridge Assay
ECL, biotin Ru labeled Bridge Assay, Cell platform/LBA
ELISA, Double antibody sandwich method
Why Choose Us
It can be tough on the way to approval, and that is why we are here – we not only ease things up and give you “the hand”, but we also guide you throughout the process and provide “know-how”.
Our leadership team has 30 years of experience in large molecule bioanalysis with our core technical team consists of 5-13 years of experience. We have rich technical experience and have had a long-term collaboration with world-class pharmaceutical companies. The team has passed multiple FDA, EMA, OECD, The CFDA audits and has supported hundreds of domestic and overseas multi-site clinical trials.
Up to now, the company has three laboratories in Ningbo, Shanghai, and New Jersey operating simultaneously with 130+ employees. Several core business platforms (FACS / qPCR / ddPCR / ELISA / MSD / EnVision / Cell Assay / Luminex) are running with very mature operations, supporting sample analysis of more than 100 clinical projects and covering various popular research categories. Cases include cytokines, peptides, recombinant proteins, fusion proteins, monoclonal antibodies, bispecific antibodies, nano-antibodies, ADC and CAR-T, etc.